Galapagos has been granted a patent for compounds designed to treat various inflammatory, autoimmune, and proliferative diseases. The patent includes a method for treating specific cancers, such as ovarian, breast, prostate, and lung cancer, using these compounds. GlobalData’s report on Galapagos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Galapagos, Peptide pharmacophores was a key innovation area identified from patents. Galapagos's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Compounds for treating various inflammatory and proliferative diseases
The granted patent US12065443B2 outlines a method for treating various types of cancer, specifically ovarian, breast, prostate, and lung cancer. The treatment involves administering an effective amount of a compound defined by a specific chemical structure, referred to as Formula I. The claims detail various substituents and modifications that can be made to the compound, including options for R1, R2, R3a, R3b, R5a, R5b, and Rb, which can include a range of functional groups such as alkyl, halo, and heterocyclic moieties. Additionally, the patent specifies that the method may include the administration of a pharmaceutical composition containing a pharmaceutically acceptable carrier along with the active compound.
Further claims in the patent indicate that the treatment may be enhanced by co-administering a therapeutic agent, with paclitaxel being specifically mentioned as a potential adjunct therapy. The claims also emphasize the versatility of the method, allowing for the treatment of different cancer types, including breast, ovarian, prostate, and lung cancers. Moreover, the patent includes a claim for a method of inhibiting Salt-Inducible Kinase, suggesting a broader application of the compounds beyond just cancer treatment. Overall, the patent presents a comprehensive approach to cancer therapy through the use of specific chemical compounds and their derivatives.
To know more about GlobalData’s detailed insights on Galapagos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
